

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC

Petitioner,

v.

KAKEN PHARMACEUTICAL CO., LTD. and
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

Patent Owner

U.S. Patent No. 7,214,506

Issue Date: May 8, 2007

Title: Method for Treating Onychomycosis

DECLARATION OF MAURIZIO DEL POETA, M.D.

Contents

I.	Qualifications, Background, and Experience	1
II.	Scope of Assignment	2
III.	Materials Considered	3
IV.	Summary of Opinions	9
V.	Legal Principles Used in Analysis	10
A.	Patent Claims in General	10
B.	Person of Ordinary Skill in the Art	11
C.	Claim Construction.....	12
D.	Prior Art.....	13
E.	Priority	13
F.	Patentability	14
VI.	A Person of Ordinary Skill in the Relevant Art	17
A.	Relevant Field.....	18
B.	Person of Ordinary Skill in the Art	18
VII.	Background of the Relevant Technology.....	19
VIII.	The '506 Patent.....	23
A.	The Claims of the '506 Patent	26
B.	Problem Addressed by the '506 Patent	28
C.	Solution Set Forth in the '506 Patent	29
IX.	Priority Date of the '506 Patent	34
X.	Obviousness Analysis	37
A.	Summary of Opinions.....	37
B.	Ground 1: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over Japanese Pat. App. Pub. No. 10- 226639 in View of Ogura 39	
i.	Summary of JP '639	39
ii.	Summary of Ogura.....	42

iii.	The Combination of JP '639 and Ogura	44
C.	Ground 2: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over U.S. Pat. No. 5,391,367 in View of Ogura	47
i.	Summary of the '367 Patent.....	47
ii.	Summary of Ogura.....	48
iii.	The Combination of the '367 Patent and Ogura	48
D.	Ground 3: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over Hay 1985 in View of Ogura.....	51
i.	Summary of Hay 1985	51
ii.	Summary of Ogura.....	52
iii.	The Combination of Hay 1985 and Ogura.....	52
E.	Ground 4: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious Over JP '639 in view of the Kaken Abstracts.....	55
i.	Summary of JP '639.....	55
ii.	Summary of the Kaken Abstracts	55
iii.	The Combination of JP'639 and the Kaken Abstracts.....	57
F.	Ground 5: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious over the '367 Patent in View of the Kaken Abstracts.....	60
i.	Summary of the '367 Patent.....	60
ii.	Summary of the Kaken Abstracts	60
iii.	The Combination of the '367 Patent and the Kaken Abstracts.....	60
G.	Ground 6: The Methods of Claims 1 and 2 of the '506 Patent Would Have Been Obvious over the Hay 1985 in view of the Kaken Abstracts.	62
i.	Summary of Hay 1985	62
ii.	Summary of the Kaken Abstracts	63
iii.	The Combination of Hay 1985 and the Kaken Abstracts	63
H.	Secondary Considerations	65
i.	The Alleged Unexpected Results Relied on by the Applicants During Prosecution Were Actually Known Beneficial Results of the Use of KP-103	
	66	
ii.	The Data Presented in the '506 Specification is Flawed and Does Not	

Provide Evidence of an Unexpected Effect.....	69
iii. Contrary to the Applicants' Argument During Prosecution, the Data Demonstrate That the Claimed Compounds Do Not Eradicate the Infection 72	
XI. Claim Charts.....	75
XII. Conclusions.....	75

1. I, Maurizio Del Poeta, M.D., do declare and state as follows.

I. Qualifications, Background, and Experience

2. I am over the age of eighteen (18) and otherwise competent to make this declaration.

3. My name is Maurizio Del Poeta. I am currently a Professor at the College of Medicine at the Department of Molecular Genetics and Microbiology at Stony Brook University. I am also a Professor and Research Physiologist at VA Medical Center in New York. In addition, I co-founded and serve as the Chief Scientific Officer of MicroRid Technologies, Inc. I have published at least 80 peer-reviewed journal articles and many other chapters and abstracts. I understand that my declaration is being submitted in connection with a Petition for *Inter Partes* Review of U.S. Patent No. 7,214,506 (the “506 patent”) (Ex. 1001).

4. I received a M.D. from the University of Ancona School of Medicine in Ancona, Italy.

5. A more complete recitation of my professional experience including a list of my journal publications, patents, conference proceedings, book authorship, and committee memberships may be found in my Curriculum Vitae and Publication List, which are attached to my declaration as Appendix A.

6. [intentionally omitted]

7. [intentionally omitted]

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.